Oxford Biomedica reports 10% revenue growth in first half

Oxford Biomedica reported H1 2026 revenue of £79.8 million, up 9% year over year, with manufacturing-services revenue rising 20% to £43.1 million; it reiterated full-year constant-currency revenue guidance of £180-200 million and a mid-single-digit EBITDA margin excluding one-offs. Adjusted operating EBITDA loss narrowed to £2.5 million from £3.9 million, but gross margin fell 600bps to 37%, operating loss widened to £29.1 million after a £7.6 million France impairment, and cash declined to £75.3 million from £96.9 million at year-end. The company added 17 clients in H1, held revenue backlog of about £193 million, and expects activity at its delayed North Carolina facility to increase in H2.

Analysis

OXB’s investable question is no longer demand generation but conversion of signed programmes into higher-margin manufacturing revenue. The widening client base improves long-duration funnel value, but early-stage development work is low-revenue and can disappear through clinical attrition; the near-term earnings inflection depends on whether the newly operational North Carolina asset ramps utilization quickly enough to absorb fixed costs. The France impairment is a more important signal than the modest EBITDA improvement: it implies capacity assumptions have already been reset lower, limiting confidence in a smooth path to the 2030 revenue target.

Liquidity is the central risk over the next 6-12 months. First-half operating cash outflow annualizes near £47m before capex, implying roughly 18-20 months of cash runway at an unchanged rate; improved second-half working capital or customer prepayments are therefore necessary to avoid the market beginning to discount an equity raise. With £168m contractually covered against the low end of annual guidance, OXB must execute and/or convert an additional £12-32m during H2, while recovering gross margin from 37%, for guidance to translate into a credible valuation rerating.

Consensus may overvalue the client-signing metric and undervalue manufacturing mix, asset utilization and cash conversion. A successful Durham ramp could create operating leverage and make OXB a differentiated UK/US vector-capacity alternative to larger CDMOs such as Lonza (LONN) and Charles River (CRL), but another ramp delay or further underutilization would turn the fixed-cost base into a financing problem. BABA has no actionable implication here: the supplied headline is inconsistent with the underlying content, so it should not enter an AI-semiconductor thesis on this source.

Key Decisions for Investors

• Keep OXB on watch rather than initiate immediately; enter a 6-12 month long only after the next update demonstrates Durham client manufacturing activity, confirms full-year revenue within guidance, and shows operating cash burn materially below the first-half run rate. The upside case is multiple expansion on credible EBITDA breakeven; the downside is dilution if cash conversion does not improve.
• For an existing OXB position, reduce exposure if full-year gross margin remains below 37% or if management lowers the £180-200m revenue range. Either outcome would indicate that manufacturing mix is not offsetting idle-capacity costs and would materially weaken the medium-term operating-leverage thesis.
• Use LONN or CRL as relative-quality alternatives for cell-and-gene-therapy CDMO exposure over the next 3-6 months; their diversified revenue bases reduce binary site-ramp risk. A long OXB versus short LONN pair is premature until OXB provides evidence that Durham utilization is rising and cash burn is inflecting.
• Do not take a BABA position based on this item. Require an independently sourced disclosure covering chip specifications, production partner, volume availability and customer adoption before assigning any semiconductor revenue or valuation impact.